Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,721
  • Shares Outstanding, K 148,369
  • Annual Sales, $ 20,650 K
  • Annual Income, $ -101,250 K
  • 60-Month Beta 2.10
  • Price/Sales 27.27
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.39
  • Prior Year -0.25
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +11.44%
on 01/17/20
3.58 -15.64%
on 01/02/20
-0.19 (-5.92%)
since 12/20/19
3-Month
1.38 +118.84%
on 11/14/19
3.58 -15.64%
on 01/02/20
+0.64 (+26.89%)
since 10/22/19
52-Week
1.38 +118.84%
on 11/14/19
9.95 -69.65%
on 01/28/19
-5.91 (-66.18%)
since 01/22/19

Most Recent Stories

More News
Hopeful New Therapies For Pancreatic Cancer Expected to be a Big Boon for Biotechs

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and...

SNGXD : 4.1500 (-5.68%)
ONCY : 3.35 (-5.63%)
ONC.TO : 4.40 (-6.58%)
MNK : 5.59 (-7.45%)
GNPX : 1.89 (+64.35%)
SNGX : 2.44 (+2.09%)
BCRX : 3.02 (+3.07%)
BioCryst Strengthens Commercial Rare Disease Leadership

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States.

BCRX : 3.02 (+3.07%)
BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for hereditary angioedema (HAE), and BCX9930, an oral Factor...

JPM : 136.68 (-0.12%)
BCRX : 3.02 (+3.07%)
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

BCRX : 3.02 (+3.07%)
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted two newly-hired employees options to purchase an aggregate of 20,000...

BCRX : 3.02 (+3.07%)
BioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 38 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 5:00 p.m....

JPM : 136.68 (-0.12%)
BCRX : 3.02 (+3.07%)
Look for Shares of Biocryst Pharm to Potentially Pullback after Yesterday's 3.13% Rise

Biocryst Pharm (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $3.21 to a high of $3.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $3.30...

BCRX : 3.02 (+3.07%)
BioCryst Submits NDA for Hereditary Angioedema Candidate

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

INVA : 14.36 (-0.90%)
ANIK : 45.71 (-0.39%)
BCRX : 3.02 (+3.07%)
GH : 84.61 (+1.08%)
BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral, once daily berotralstat (BCX7353)...

BCRX : 3.02 (+3.07%)
Implied Volatility Surging for BioCryst (BCRX) Stock Options

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

BCRX : 3.02 (+3.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade BCRX with:

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

2nd Resistance Point 3.38
1st Resistance Point 3.20
Last Price 3.02
1st Support Level 2.89
2nd Support Level 2.76

See More

52-Week High 9.95
Fibonacci 61.8% 6.68
Fibonacci 50% 5.66
Fibonacci 38.2% 4.65
Last Price 3.02
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar